Loading...

RHÖN-KLINIKUM

XTRA:RHK
Snowflake Description

Flawless balance sheet with questionable track record.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
RHK
XTRA
€2B
Market Cap
  1. Home
  2. DE
  3. Healthcare
Company description

RHÖN-KLINIKUM Aktiengesellschaft, together with its subsidiaries, builds, acquires, and operates primarily acute-care hospitals in Germany. The last earnings update was 54 days ago. More info.


Add to Portfolio Compare Print
RHK Share Price and Events
7 Day Returns
1%
XTRA:RHK
1.7%
DE Healthcare
1.5%
DE Market
1 Year Returns
4.3%
XTRA:RHK
-25.6%
DE Healthcare
-5.8%
DE Market
RHK Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
RHÖN-KLINIKUM (RHK) 1% 2.7% 5.9% 4.3% 1.2% 11.9%
DE Healthcare 1.7% 0.5% -2.5% -25.6% -16.5% 33.1%
DE Market 1.5% 1.3% 2.2% -5.8% 17.6% 8.7%
1 Year Return vs Industry and Market
  • RHK outperformed the Healthcare industry which returned -25.6% over the past year.
  • RHK outperformed the Market in Germany which returned -5.8% over the past year.
Price Volatility
RHK
Industry
5yr Volatility vs Market

RHK Value

 Is RHÖN-KLINIKUM undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of RHÖN-KLINIKUM to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for RHÖN-KLINIKUM.

XTRA:RHK Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 6 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 5%
Perpetual Growth Rate 10-Year DE Government Bond Rate 0.2%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for XTRA:RHK
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year DE Govt Bond Rate 0.2%
Equity Risk Premium S&P Global 6%
Healthcare Unlevered Beta Simply Wall St/ S&P Global 0.64
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 0.64 (1 + (1- 30%) (6.45%))
0.778
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
0.8
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 0.23% + (0.8 * 5.96%)
5%

Discounted Cash Flow Calculation for XTRA:RHK using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for RHÖN-KLINIKUM is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

XTRA:RHK DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (EUR, Millions) Source Present Value
Discounted (@ 5%)
2019 45.00 Analyst x2 42.86
2020 58.33 Analyst x3 52.91
2021 5.00 Analyst x1 4.32
2022 -0.90 Est @ -117.9% -0.74
2023 -1.63 Est @ -82.46% -1.28
2024 -2.58 Est @ -57.66% -1.92
2025 -3.61 Est @ -40.29% -2.57
2026 -4.63 Est @ -28.14% -3.13
2027 -5.54 Est @ -19.63% -3.57
2028 -6.30 Est @ -13.67% -3.87
Present value of next 10 years cash flows €83.01
XTRA:RHK DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2028 × (1 + g) ÷ (Discount Rate – g)
= €-6.30 × (1 + 0.23%) ÷ (5% – 0.23%)
€-132.33
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= €-132.33 ÷ (1 + 5%)10
€-81.27
XTRA:RHK Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= €83.01 + €-81.27
€1.74
Equity Value per Share
(EUR)
= Total value / Shares Outstanding
= €1.74 / 66.94
€0.03
XTRA:RHK Discount to Share Price
Calculation Result
Value per share (EUR) From above. €0.03
Current discount Discount to share price of €26.55
= -1 x (€26.55 - €0.03) / €0.03
-101012.6%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

  • The current share price of RHÖN-KLINIKUM is above its future cash flow value.
Often investors are willing to pay a premium for a company that has a high dividend or the potential for future growth.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for RHÖN-KLINIKUM's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are RHÖN-KLINIKUM's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
XTRA:RHK PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-03-31) in EUR €0.71
DB:RHK Share Price ** DB (2019-06-25) in EUR €26.35
Germany Healthcare Industry PE Ratio Median Figure of 10 Publicly-Listed Healthcare Companies 29.06x
Germany Market PE Ratio Median Figure of 425 Publicly-Listed Companies 19.8x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of RHÖN-KLINIKUM.

XTRA:RHK PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= DB:RHK Share Price ÷ EPS (both in EUR)

= 26.35 ÷ 0.71

37.27x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • RHÖN-KLINIKUM is overvalued based on earnings compared to the DE Healthcare industry average.
  • RHÖN-KLINIKUM is overvalued based on earnings compared to the Germany market.
Price based on expected Growth
Does RHÖN-KLINIKUM's expected growth come at a high price?
Raw Data
XTRA:RHK PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section 37.27x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 6 Analysts
1.8%per year
Germany Healthcare Industry PEG Ratio Median Figure of 7 Publicly-Listed Healthcare Companies 1.42x
Germany Market PEG Ratio Median Figure of 272 Publicly-Listed Companies 1.45x

*Line of best fit is calculated by linear regression .

XTRA:RHK PEG (Price to Earnings to Growth) Ratio Calculation
Calculation Outcome
PEG Ratio

= PE Ratio ÷ Net Income Annual Growth Rate

= 37.27x ÷ 1.8%

20.9x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • RHÖN-KLINIKUM is poor value based on expected growth next year.
Price based on value of assets
What value do investors place on RHÖN-KLINIKUM's assets?
Raw Data
XTRA:RHK PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-03-31) in EUR €17.09
DB:RHK Share Price * DB (2019-06-25) in EUR €26.35
Germany Healthcare Industry PB Ratio Median Figure of 12 Publicly-Listed Healthcare Companies 1.59x
Germany Market PB Ratio Median Figure of 574 Publicly-Listed Companies 1.8x
XTRA:RHK PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= DB:RHK Share Price ÷ Book Value per Share (both in EUR)

= 26.35 ÷ 17.09

1.54x

* Primary Listing of RHÖN-KLINIKUM.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • RHÖN-KLINIKUM is good value based on assets compared to the DE Healthcare industry average.
X
Value checks
We assess RHÖN-KLINIKUM's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Healthcare industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Healthcare industry average (and greater than 0)? (1 check)
  5. RHÖN-KLINIKUM has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

RHK Future Performance

 How is RHÖN-KLINIKUM expected to perform in the next 1 to 3 years based on estimates from 6 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
1.8%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is RHÖN-KLINIKUM expected to grow at an attractive rate?
  • RHÖN-KLINIKUM's earnings growth is expected to exceed the low risk savings rate of 0.2%.
Growth vs Market Checks
  • RHÖN-KLINIKUM's earnings growth is positive but not above the Germany market average.
  • RHÖN-KLINIKUM's revenue growth is positive but not above the Germany market average.
Annual Growth Rates Comparison
Raw Data
XTRA:RHK Future Growth Rates Data Sources
Data Point Source Value (per year)
XTRA:RHK Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 6 Analysts 1.8%
XTRA:RHK Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 6 Analysts 2.6%
Germany Healthcare Industry Earnings Growth Rate Market Cap Weighted Average 8.7%
Germany Healthcare Industry Revenue Growth Rate Market Cap Weighted Average 6%
Germany Market Earnings Growth Rate Market Cap Weighted Average 12.6%
Germany Market Revenue Growth Rate Market Cap Weighted Average 5.1%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
XTRA:RHK Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (2 months ago) See Below
Future Estimates Average of up to 6 Analyst Estimates (S&P Global) See Below
All numbers in EUR Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
XTRA:RHK Future Estimates Data
Date (Data in EUR Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-12-31 1,459 129 52 3
2022-12-31 1,413 111 47 3
2021-12-31 1,368 115 51 5
2020-12-31 1,323 111 47 6
2019-12-31 1,280 100 48 6
XTRA:RHK Past Financials Data
Date (Data in EUR Millions) Revenue Cash Flow Net Income *
2019-03-31 1,430 46 47
2018-12-31 1,411 50 49
2018-09-30 1,412 24 55
2018-06-30 1,385 54 36
2018-03-31 1,374 63 37
2017-12-31 1,362 80 35
2017-09-30 1,340 69 2
2017-06-30 1,330 87 4
2017-03-31 1,334 96 14
2016-12-31 1,319 109 56
2016-09-30 1,291 114 101
2016-06-30 1,276 101 105

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • RHÖN-KLINIKUM's earnings are expected to grow by 1.8% yearly, however this is not considered high growth (20% yearly).
  • RHÖN-KLINIKUM's revenue is expected to grow by 2.6% yearly, however this is not considered high growth (20% yearly).
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
XTRA:RHK Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (2 months ago) See Below
Future Estimates Average of up to 6 Analyst Estimates (S&P Global) See Below

All data from RHÖN-KLINIKUM Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

XTRA:RHK Future Estimates Data
Date (Data in EUR Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-12-31 0.78 0.78 0.78 1.00
2022-12-31 0.70 0.70 0.70 1.00
2021-12-31 0.72 1.03 0.36 4.00
2020-12-31 0.65 0.90 0.43 6.00
2019-12-31 0.70 0.76 0.66 4.00
XTRA:RHK Past Financials Data
Date (Data in EUR Millions) EPS *
2019-03-31 0.71
2018-12-31 0.73
2018-09-30 0.83
2018-06-30 0.54
2018-03-31 0.56
2017-12-31 0.53
2017-09-30 0.02
2017-06-30 0.06
2017-03-31 0.21
2016-12-31 0.84
2016-09-30 1.51
2016-06-30 1.54

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if RHÖN-KLINIKUM will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess RHÖN-KLINIKUM's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
RHÖN-KLINIKUM has a total score of 1/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

RHK Past Performance

  How has RHÖN-KLINIKUM performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare RHÖN-KLINIKUM's growth in the last year to its industry (Healthcare).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • RHÖN-KLINIKUM's year on year earnings growth rate was negative over the past 5 years and the most recent earnings are below average.
  • RHÖN-KLINIKUM's 1-year earnings growth exceeds its 5-year average (26.9% vs -75.2%)
  • RHÖN-KLINIKUM's earnings growth has exceeded the DE Healthcare industry average in the past year (26.9% vs 13.5%).
Earnings and Revenue History
RHÖN-KLINIKUM's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from RHÖN-KLINIKUM Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

XTRA:RHK Past Revenue, Cash Flow and Net Income Data
Date (Data in EUR Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-03-31 1,430.02 47.33 5.10
2018-12-31 1,410.68 48.99 5.40
2018-09-30 1,411.70 55.20 2.80
2018-06-30 1,385.34 36.16 4.10
2018-03-31 1,373.90 37.29 5.80
2017-12-31 1,362.31 35.15 5.80
2017-09-30 1,339.52 1.54 5.90
2017-06-30 1,330.16 4.29 4.60
2017-03-31 1,333.91 14.36 4.50
2016-12-31 1,319.36 56.43 6.30
2016-09-30 1,291.15 101.41 6.10
2016-06-30 1,276.33 104.92 6.10
2016-03-31 1,251.18 103.14 6.80
2015-12-31 1,239.77 85.38 4.70
2015-09-30 1,249.67 65.99 4.90
2015-06-30 1,247.63 62.45 6.30
2015-03-31 1,300.40 -138.40 6.50
2014-12-31 1,665.88 1,225.71 10.10
2014-09-30 2,170.68 1,244.86 14.80
2014-06-30 2,660.59 1,249.64 13.40
2014-03-31 3,098.36 1,459.27 16.90
2013-12-31 3,222.93 86.65 23.40
2013-09-30 3,189.49 87.47 23.80
2013-06-30 3,167.16 90.02 23.80
2013-03-31 3,117.38 80.48 21.80
2012-12-31 3,037.91 90.12 20.30
2012-09-30 2,962.66 107.93 18.60
2012-06-30 2,903.82 123.29 18.60

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • RHÖN-KLINIKUM has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).
  • RHÖN-KLINIKUM used its assets less efficiently than the DE Healthcare industry average last year based on Return on Assets.
  • RHÖN-KLINIKUM's use of capital deteriorated last year versus 3 years ago (Return on Capital Employed).
X
Past performance checks
We assess RHÖN-KLINIKUM's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Healthcare industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
RHÖN-KLINIKUM has a total score of 2/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

RHK Health

 How is RHÖN-KLINIKUM's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up RHÖN-KLINIKUM's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • RHÖN-KLINIKUM is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • RHÖN-KLINIKUM's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of RHÖN-KLINIKUM's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • High level of physical assets or inventory.
  • Debt is covered by short term assets, assets are 5.1x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from RHÖN-KLINIKUM Company Filings, last reported 2 months ago.

XTRA:RHK Past Debt and Equity Data
Date (Data in EUR Millions) Total Equity Total Debt Cash & Short Term Investments
2019-03-31 1,168.22 100.24 255.18
2018-12-31 1,159.22 99.83 262.26
2018-09-30 1,155.91 0.00 212.14
2018-06-30 1,126.96 0.00 237.52
2018-03-31 1,135.38 0.00 242.22
2017-12-31 1,125.26 0.00 234.67
2017-09-30 1,115.65 0.00 287.00
2017-06-30 1,107.06 10.06 291.83
2017-03-31 1,121.84 10.00 294.23
2016-12-31 1,113.38 10.00 274.06
2016-09-30 1,137.22 10.00 346.45
2016-06-30 1,124.47 10.00 311.29
2016-03-31 1,159.37 10.00 386.18
2015-12-31 1,108.71 157.63 488.66
2015-09-30 1,072.30 156.17 708.54
2015-06-30 1,238.19 154.71 688.08
2015-03-31 1,281.71 153.26 724.02
2014-12-31 1,248.92 157.42 698.28
2014-09-30 1,222.43 155.92 2,340.40
2014-06-30 2,864.45 164.21 2,339.57
2014-03-31 3,071.77 409.56 2,614.80
2013-12-31 1,666.69 836.76 35.02
2013-09-30 1,644.21 792.52 45.97
2013-06-30 1,628.47 907.37 155.91
2013-03-31 1,634.70 999.08 242.81
2012-12-31 1,606.87 1,034.67 266.78
2012-09-30 1,586.33 973.61 240.36
2012-06-30 1,569.39 1,186.51 416.17
  • RHÖN-KLINIKUM's level of debt (9%) compared to net worth is satisfactory (less than 40%).
  • The level of debt compared to net worth has been reduced over the past 5 years (13.3% vs 9% today).
  • Debt is well covered by operating cash flow (43.1%, greater than 20% of total debt).
  • Interest payments on debt are well covered by earnings (EBIT is 26.7x coverage).
X
Financial health checks
We assess RHÖN-KLINIKUM's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. RHÖN-KLINIKUM has a total score of 6/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

RHK Dividends

 What is RHÖN-KLINIKUM's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
1.1%
Current annual income from RHÖN-KLINIKUM dividends. Estimated to be 1.12% next year.
If you bought €2,000 of RHÖN-KLINIKUM shares you are expected to receive €22 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • RHÖN-KLINIKUM's pays a lower dividend yield than the bottom 25% of dividend payers in Germany (1.44%).
  • RHÖN-KLINIKUM's dividend is below the markets top 25% of dividend payers in Germany (3.81%).
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
XTRA:RHK Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 6 Analyst Estimates (S&P Global) See Below
Germany Healthcare Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 1.7%
Germany Market Average Dividend Yield Market Cap Weighted Average of 328 Stocks 3.2%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.8%
Germany Bottom 25% Dividend Yield 25th Percentile 1.4%
Germany Top 25% Dividend Yield 75th Percentile 3.8%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

XTRA:RHK Future Dividends Estimate Data
Date (Data in €) Dividend per Share (annual) Avg. No. Analysts
2023-12-31
2022-12-31 0.42 1.00
2021-12-31 0.30 3.00
2020-12-31 0.29 6.00
2019-12-31 0.27 4.00
XTRA:RHK Past Annualized Dividends Data
Date (Data in €) Dividend per share (annual) Avg. Yield (%)
2019-03-29 0.290 1.117
2018-03-29 0.220 0.924
2017-04-07 0.350 1.253
2016-04-14 0.800 3.075
2015-04-17 0.800 3.101
2014-04-29 0.250 1.069
2013-04-25 0.250 1.272
2013-04-24 0.250 1.520
2012-08-09 0.450 2.872
2012-04-25 0.450 2.309
2011-04-27 0.370 2.394
2010-06-09 0.300 1.801
2009-04-23 0.350 2.074

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Dividends per share have been volatile in the past 10 years (annual drop of over 20%).
  • Dividends per share have fallen over the past 10 years.
Current Payout to shareholders
What portion of RHÖN-KLINIKUM's earnings are paid to the shareholders as a dividend.
  • Dividends paid are well covered by earnings (2.4x coverage).
Future Payout to shareholders
  • Dividends after 3 years are expected to be well covered by earnings (2.2x coverage).
X
Income/ dividend checks
We assess RHÖN-KLINIKUM's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can RHÖN-KLINIKUM afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. RHÖN-KLINIKUM has a total score of 2/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

RHK Management

 What is the CEO of RHÖN-KLINIKUM's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Stephan Holzinger
COMPENSATION €2,271,000
TENURE AS CEO 2.3 years
CEO Bio

Mr. Stephan Holzinger serves as a Management Consultant at Lenggries. Mr. Holzinger has been Chairman of Management Board at Rhön-Klinikum Aktiengesellschaft since February 1, 2017. He is Chief Executive Officer of Rhön-Klinikum Aktiengesellschaft since February 4, 2017. He is Member of Management Board of Rhön-Klinikum Aktiengesellschaft since February 1, 2017. He served as a Member of Supervisory Board at Rhön-Klinikum Aktiengesellschaft from July 3, 2013 to January 31, 2017.

CEO Compensation
  • Stephan's compensation has been consistent with company performance over the past year, both up more than 20%.
  • Stephan's remuneration is higher than average for companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the RHÖN-KLINIKUM management team in years:

2.3
Average Tenure
66
Average Age
  • The tenure for the RHÖN-KLINIKUM management team is about average.
Management Team

Stephan Holzinger

TITLE
Chairman of Board of Management & CEO
COMPENSATION
€2M
TENURE
2.3 yrs

Bernd Griewing

TITLE
Chief Medical Officer & Member of Board of Management
COMPENSATION
€1M
TENURE
3.4 yrs

Gunther Karl Weiß

TITLE
COO & Member of Management Board
COMPENSATION
€751K
AGE
52
TENURE
1.1 yrs

Jörg Demmler

TITLE
Head of Technical Controlling & Environment
AGE
66

Julian Schmitt

TITLE
Head of Investor Relations & Treasury

Elke Pfeifer

TITLE
Head of Corporate Communications and Marketing

Franz Mlynek

TITLE
Divisional Head of Major Investments
AGE
66

Esther Walter

TITLE
Head of Group Press and Public Relations

Harald Auner

TITLE
Head of Group Division
Board of Directors Tenure

Average tenure of the RHÖN-KLINIKUM board of directors in years:

9.8
Average Tenure
  • The tenure for the RHÖN-KLINIKUM board of directors is about average.
Board of Directors

Eugen Münch

TITLE
Chairman of Supervisory Board
COMPENSATION
€357K
TENURE
13.8 yrs

Wolfgang Mündel

TITLE
Second Deputy Chairman of Supervisory Board
COMPENSATION
€301K

Georg Schulze-Ziehaus

TITLE
First Deputy Chairman of the Supervisory Board
COMPENSATION
€138K
TENURE
4 yrs

Frederik Wenz

TITLE
Chairman of Advisory Board
TENURE
10.6 yrs

Annette Beller

TITLE
Member of Supervisory Board
COMPENSATION
€172K
TENURE
2.3 yrs

Gerhard Ehninger

TITLE
Member of Supervisory Board
COMPENSATION
€54K

Michael Wendl

TITLE
Member of Advisory Board
COMPENSATION
€80K

Brigitte Mohn

TITLE
Member of Supervisory Board
COMPENSATION
€56K
TENURE
16.9 yrs

Georg Milbradt

TITLE
Member of Advisory Board

Stefan Härtel

TITLE
Member of Supervisory Board
COMPENSATION
€82K
TENURE
9 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
X
Management checks
We assess RHÖN-KLINIKUM's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. RHÖN-KLINIKUM has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

RHK News

Simply Wall St News

RHK Company Info

Description

RHÖN-KLINIKUM Aktiengesellschaft, together with its subsidiaries, builds, acquires, and operates primarily acute-care hospitals in Germany. Its hospitals offer treatment services primarily in the areas of cardiovascular, neurology, oncology, pulmonology, orthopedic, accident surgery; rehabilitation and nursing services to the elderly; and thoracic, tumors, and psychosomatic, as well as spinal, column, and joints diseases. As of December 31, 2018, it operated 11 hospitals and 5,369 beds/places at 5 medical sites. The company is headquartered in Bad Neustadt an der Saale, Germany.

Details
Name: RHÖN-KLINIKUM Aktiengesellschaft
RHK
Exchange: XTRA
Founded:
€1,763,828,684
66,938,470
Website: http://www.rhoen-klinikum-ag.com
Address: RHÖN-KLINIKUM Aktiengesellschaft
Salzburger Leite 1,
Bad Neustadt an der Saale,
Bavaria, 97616,
Germany
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
DB RHK Bearer Ordinary Shares Deutsche Boerse AG DE EUR 02. Jan 1992
OTCPK RHKJ.F Bearer Ordinary Shares Pink Sheets LLC US USD 02. Jan 1992
XTRA RHK Bearer Ordinary Shares XETRA Trading Platform DE EUR 02. Jan 1992
LSE 0NQH Bearer Ordinary Shares London Stock Exchange GB EUR 02. Jan 1992
SWX RHK Bearer Ordinary Shares SIX Swiss Exchange CH CHF 02. Jan 1992
WBAG RHK Bearer Ordinary Shares Wiener Boerse AG AT EUR 02. Jan 1992
BATS-CHIXE RHKD Bearer Ordinary Shares BATS 'Chi-X Europe' GB EUR 02. Jan 1992
OTCPK RKAG.Y ADR Pink Sheets LLC US USD 17. Feb 2010
Number of employees
Current staff
Staff numbers
17,089
RHÖN-KLINIKUM employees.
Industry
Health Care Facilities
Healthcare
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/06/26 02:30
End of day share price update: 2019/06/25 00:00
Last estimates confirmation: 2019/05/10
Last earnings filing: 2019/05/03
Last earnings reported: 2019/03/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.